Johnson & Johnson Reports 2019 Fourth-Quarter And Full Year Results:

Go back to Johnson & Johnson Reports 2019 Fourth-Quarter And Full Year Results:

Cantor Fitzgerald Reiterates Overweight Rating on Johnson & Johnson (JNJ) Following 4Q

January 23, 2020 6:39 AM EST

Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $168.00 price target on Johnson & Johnson (NYSE: JNJ) following the company's 4Q earnings report. Chen continues to believe that upward earnings revisions to JNJ's Pharma business and multiple expansion, driven by diminishing headlines... More

Johnson & Johnson (JNJ) Tops Q4 EPS by 1c, Offers FY20 Guidance

January 22, 2020 6:33 AM EST

(Updated - January 22, 2020 6:33 AM EST)

Johnson & Johnson (NYSE: JNJ) reported Q4 EPS of $1.88, $0.01 better than the analyst estimate of $1.87. Revenue for the quarter came in at $20.7 billion versus the consensus estimate of $20.77 billion.

GUIDANCE:

Johnson & Johnson sees FY2020 EPS of... More